In the context of rapid growth in the global and Chinese biopharmaceutical markets, supported by continuous technological innovations and increasingly prominent supply chain advantages, domestic biopharmaceutical companies are beginning to expand overseas and explore international markets. Since China joined the International Conference on Harmonisation (ICH) in 2017, dual filing in both China and the US has become a new trend for local enterprises applying for innovative drugs. There are many differences between China and the US in terms of regulations and requirements, with both opportunities and challenges. Along with advancements in technology and drug development, the pharmaceutical market is maturing, and the US FDA's regulatory policies and drug review systems are continually evolving. Domestic pharmaceutical companies need to continuously study these changes to develop beneficial and effective dual filing strategies for both China and the US.

Among the various elements of biopharmaceutical application materials, cell bank testing is a very important aspect. Both Chinese and foreign regulations have essentially the same overall requirements: the Master Cell Bank (MCB) and Working Cell Bank (WCB) are critical risk control points for key materials, and these are mandatory requirements. The End-of-Production Cell (EOPC) and Unprocessed Bulk (UPB) testing are also mandatory process product control points. EOPC, as a part of the process research data, only requires one batch (retesting is needed if the process changes), while UPB, as a process product, requires testing for each batch. Due to differences in the industrial phase of biopharmaceuticals, regulatory systems, and the application of new technologies, there are variations in the applicability and details of the guidelines between China and the US, as well as in the execution and communication. The key differences in the technical methods and execution of cell bank testing are shown in the table below:

Difference	China	USA
細胞形態觀察和血(xue)吸附試驗	要求	僅形態觀(guan)察
EOPC檢定	IND階段	可在BLA階段
鼠源(yuan)病毒檢查	可(ke)用(yong)動物抗體產生試驗（無(wu)病毒具體要求） 雜(za)交瘤細(xi)胞及鼠源性單(dan)克隆抗體(ti)制品：細(xi)胞/動物/雞胚感(gan)染性(xing)試(shi)驗； 鼠源第二法Q-PCR法-8種	嚙齒類動物材料和細胞應做抗體產生試驗 MAP-16種，HAP-6種，RAP-11種； 也可用充分驗證的Q-PCR法
牛(niu)源病毒檢查	指示細胞感(gan)染法(fa)及(ji)免疫熒光法(fa)-6種	指(zhi)示細(xi)胞感染法及免(mian)疫熒光法-7種 基礎(chu)上(shang)再增(zeng)加BPyV，IBRV等
豬(zhu)源病毒檢(jian)查	PPV、PCV1/2、TTSuV1/2（未指定方法）	指示細胞感(gan)染法及免疫熒光(guang)法PPV、PADV、TGEV、PHEV； 豬牛共患BVDV、Reo3、rabies virus
人源病(bing)毒檢(jian)查	16種病毒（可用Q-PCR法）	Q-PCR法-18種 易感人類的(de)猿猴病(bing)毒SV40等(deng)

Canvest Bio has completed the optimization and upgrading of relevant testing technologies in compliance with 9 CFR, ICH guidelines, United States Pharmacopeia (USP) requirements, and current USP edition references. We provide comprehensive cell bank testing services covering:

Test	Testing Item	主細胞庫MCB	工作細(xi)胞庫WCB	生產終末細胞EOPC	收獲液 UPB
無菌檢查-細菌真菌（Sterility Test）	無(wu)菌檢查直接(jie)(jie)接(jie)(jie)種法（Sterility Test (Direct Inoculation)）+方法適用性直接(jie)接(jie)種法（Method Verification for Sterility (Direct Inoculation)）	√	√	√
	無菌檢(jian)查薄膜過濾法（Sterility Test ( Membrane Filtration)）+方法(fa)適用薄膜過濾法(fa)（Method Verification for Sterility ( Membrane Filtration)）				√
無菌檢查-分枝桿菌（Sterility Test）	無菌檢查-分枝桿菌檢測（Mycobacteria Testing）	（√）	（√）	（√）	（√）
支原體檢測（Mycoplasma）	支原體檢測培養法(fa)含干擾試驗（ Detection of Mycoplasma by direct culture method IncludingMycoplasmastasis）	√	√	√	√
	支原(yuan)體檢測指示細胞(bao)培養法（ Detection of Mycoplasma by indication cell culture method）	√	√	√	√
外源(不(bu)定)病毒檢測（AdventitiousVirus）	體外不(bu)同指示細胞接種培(pei)養法28天（In-Vitro Indicator Cell Culture Assayfor Adventitious Virus Contaminants）	√	√	√	√
	乳鼠(shu)和成(cheng)鼠(shu) Detection of viruses by sucking mice and adult mice	√		√	√
	雞胚 Detection of viruses by embryonated chicken eggs	√		√	√
	豚鼠Detection of viruses by guinea pigs	√		√	√
逆轉錄(lu)病(bing)毒檢(jian)測（Retrovirus)	逆轉錄酶活性(xing)檢查（Detection of Reverse Transcriptase Activity—PERT Assay）	√		√	√
	感染性試驗（Infectivity Test forRetroviruses）	√		√	√
	逆(ni)轉(zhuan)錄病毒檢測-透射(she)電(dian)鏡觀察（Retroviruses-TEM）	√		√
	病毒顆粒(li)負染色電鏡定量(liang)(Quantitation of Viral Particles by Negative Stain Electron Microscopy)				√
鼠源病毒檢測(ce) （Murine viruses）	Q-PCR法檢測16種鼠(shu)源(yuan)病毒（Q-PCR based Detection of  LCMV，HFRS，ECTV，HVJ，PVM，Reo-3，MADV，MuLV，MVM，TMEV，MPyV，MTLV，MHV，MRV，LDV viruses）	√
牛源病(bing)毒檢測 （Bovineviruses）	細胞培養法(fa)及熒(ying)光抗(kang)體檢(jian)測8種牛源病毒（In vitro assay for the detection ofBVDV，BAV3，BPV，Rabies，Reo3，PI3，BTV，BRSV viruses）	√
	Q-PCR法檢測2種(zhong)牛源病(bing)毒（Q-PCR based Detection of BPyV，IBRV viruses）	√
豬源(yuan)病(bing)毒檢測 （Porcineviruses）	細胞(bao)培養法、熒光抗(kang)體(ti)法及Q-PCR法檢(jian)測6種豬源病(bing)毒(du)（In vitroassay and Q-PCR based Detection of PPV，PHEV，PCV，PADV，TGEV，TTSuV viruses）	√
其他病(bing)毒(du)檢測	Q-PCR法檢(jian)測杯狀病(bing)毒（Q-PCR based Detection of Vesivirus2117 ）	√
細胞(bao)鑒別 （CellIdentity）	DNA條(tiao)形碼 （ DNA Barcoding by CO1 geneamplification）	√	√	√